Research Article
Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients
Table 1
Baseline characteristics of recipients and donors.
| | Variable | EVT () | TDF () | value |
| | Recipient age (years) | | | 0.878 | | Recipient gender (, % female) | 113 (14.2%) | 11 (10.1%) | 0.246 | | Recipient BMI (kg/m2) | | | 0.841 | | Recipient HCC (, %) | 368 (46.1%) | 48 (44.0%) | 0.683 | | Hypertension (, %) | 107 (13.4%) | 21 (19.3%) | 0.099 | | Diabetes mellitus (, %) | 124 (15.5%) | 23 (21.1%) | 0.139 | | MELD at transplantation | 15 (10-26) | 14 (9-26) | 0.955 | | International normalized ratio | 1.42 (1.17-2.05) | 1.48 (1.20-2.23) | 0.446 | | Bilirubin (μmoI/L) | 51 (20-290) | 48 (21-302) | 0.967 | | Creatinine (μmoI/L) | 65 (54-79) | 64 (52-75) | 0.071 | | Baseline creatinine (μmoI/L) | 72 (59-87) | 64 (53-81) | 0.001 | | Baseline eGFR (mL/min/1.73 m2) | 103 (86-114) | 108 (95-120) | 0.001 | | HBV-related indication (, %) | 778 (97.5%) | 104 (95.4%) | 0.213 | | HBsAg (log10 U/mL) | 2.58 (1.76-3.15) | 2.46 (1.89-3.33) | 0.721 | | HBV DNA detectable | 335 (42.0%) | 53 (48.6%) | 0.188 | | HBV DNA (log10 IU/mL) | | | 0.934 | | Donor age (years) | | | 0.875 | | Donor gender (, % female) | 126 (15.8%) | 17 (15.6%) | 0.959 | | Donor BMI (kg/m2) | | | 0.267 | | Cold ischemic time (hours) | | | 0.079 | | Duration of surgery (hours) | | | 0.284 | | Blood loss (100 mL) | 10 (8-16) | 10 (6-15) | 0.149 | | ABO incompatibility (, %) | 113 (14.2%) | 17 (15.6%) | 0.688 | | Recipient severe postoperative complications (, %) | 304 (38.1%) | 31 (28.4%) | 0.050 | | Follow-up (months) | 36.63 (25.58-53.57) | 44.60 (27.50-58.47) | 0.086 |
|
|
Abbreviations: ENT: entecavir; TDF: tenofovir; HBsAg: hepatitis B surface antigen; MELD: Model for End-stage Liver Disease; BMI: body mass index; HBV: hepatitis B; HCC: hepatocellular carcinoma; eGFR: estimated glomerular filtration rate.
|
